Semaglutide for Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Patients with Type 2 Diabetes and Comorbid Rheumatoid Arthritis: A Target-Trial Emulation - PubMed
4 hours ago
- #Rheumatoid Arthritis
- #Semaglutide
- #Cardiovascular Prevention
- Semaglutide significantly reduces the risk of major adverse cardiac and cerebrovascular events (MACCE) in obese adults with type 2 diabetes and rheumatoid arthritis, compared to non-GLP-1 receptor agonist therapies.
- The primary benefit is driven by a lower risk of incident heart failure, with no significant differences observed in all-cause mortality, myocardial infarction, or stroke.
- Initiation of semaglutide led to a 25% lower hazard ratio for MACCE and was also associated with reduced need for escalation of disease-modifying antirheumatic drugs (DMARDs).
- The study used a target-trial emulation design with propensity-score matching from a US database, following patients for up to two years.
- Results support semaglutide's potential for primary cardiovascular prevention in this high-risk population, though prospective studies are needed to confirm causality.